legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

## Prime Medicine, Inc. Announces Underwritten Public Offering

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company specializing in delivering a new class of differentiated one-time curative genetic therapies, has announced the commencement of an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also plans to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Prime Medicine is collaborating with J.P. Morgan, Jefferies, TD Cowen, and BMO Capital Markets as joint book-running managers for the proposed offering. Chardan is acting as the lead manager for the proposed offering.

The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023, and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and a prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will soon be filed with the SEC and will be available on the SECÔÇÖs website at www.sec.gov.

With the final prospectus supplement to be filed with the SEC, the terms of the offering will be disclosed.

Investors can obtain copies of the preliminary prospectus supplement relating to the offering from J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC, or BMO Capital Markets Corp.

However, this press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

### How AI legalese decoder Can Help

AI legalese decoder can assist Prime Medicine in navigating the complexity of the securities laws, regulations, and filing requirements with the SEC. The platform can provide real-time analysis and interpretation of the legal jargon and complex language used in legal documents, helping Prime Medicine ensure compliance and accuracy in its public offering process. By leveraging AI legalese decoder, Prime Medicine can streamline the preparation of its prospectus supplement and other relevant documents, ensuring clarity and precision in communications with investors, regulators, and underwriters. Moreover, AI legalese decoder can help Prime Medicine stay updated with the latest legal requirements and disclosures, minimizing the risk of errors or omissions in its offering materials.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link